Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson
13 nov. 2023 13h40 HE
|
Processa Pharmaceuticals, Inc.
Hanover, MD., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced today with great sadness that Virgil Thompson, Director, passed away unexpectedly on November...
Processa Pharmaceuticals to Present at the ThinkEquity Conference
13 oct. 2023 13h08 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 08h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care
17 août 2023 08h05 HE
|
Processa Pharmaceuticals, Inc.
Interim analysis of Phase 1B data suggests Processa’s novel chemotherapy treatment could improve safety and efficacy in more patients by individualizing the dosing regimen for each patient HANOVER,...
Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference
10 août 2023 16h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next...
Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
08 août 2023 08h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focusing on developing the next...
Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results
30 mars 2023 16h01 HE
|
Processa Pharmaceuticals, Inc.
Company focused on the development of Next Generation Chemotherapy drugs in 2023 and out-licensing/business development efforts for non-oncology assets.Dose escalations continue for Next Generation...
Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST
23 mars 2023 08h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 23, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a developer of Next Generation Chemotherapy drugs that provide a better...
Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine
17 mars 2023 08h30 HE
|
Processa Pharmaceuticals, Inc.
The 300 mg dose group will provide more information on the drug exposure vs adverse event relationship which is critical to FDA approval given the FDA’s Project Optimus Oncology initiative.Patients...
Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
07 mars 2023 08h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 07, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), the developer of the Next Generation Chemotherapy drugs that will provide...